Journal of Neuroinflammation

ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease

Retrieved on: 
Tuesday, April 25, 2023
ASC, Neuron, Neuroinflammation, NLRP3, Brain, Multiple sclerosis, DSM-IV codes, Journal of Neuroinflammation, Super Meat Boy, Journal, Dyskinesia, Therapy, Pharmaceutical industry, Medical imaging, PD

In the paper titled, “ASC specks exacerbate α‑synuclein pathology via amplifying NLRP3 inflammasome activities,” the authors reported data on the interplay between ASC speck formation, NLRP3 inflammasome activation, and pathological progression in a PD model (induced by human A53T mutant α-synuclein preformed fibrils, “PFFs”).

Key Points: 
  • In the paper titled, “ASC specks exacerbate α‑synuclein pathology via amplifying NLRP3 inflammasome activities,” the authors reported data on the interplay between ASC speck formation, NLRP3 inflammasome activation, and pathological progression in a PD model (induced by human A53T mutant α-synuclein preformed fibrils, “PFFs”).
  • These findings imply that targeting ASC is a promising therapeutic approach for PD.”   To read the article Click Here .
  • Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President, stated: “The research on the role of ASC Specks in propagation of alpha-synuclein pathology in Parkinson’s disease published in the Journal of Neuroinflammation provides additional support for the therapeutic potential of ZyVersa’s proprietary monoclonal antibody Inflammasome ASC Inhibitor IC 100, in neurological diseases.
  • IC 100 preclinical studies demonstrate reduced inflammatory activity and/or improved outcomes in, age-related inflammation, Alzheimer’s disease, multiple sclerosis, spinal cord injury, and two different models of brain injury.”

Emerald Health Pharmaceuticals Reports Data Showing Novel Drug Candidate is First-in-class B55α/PP2A Activator

Retrieved on: 
Thursday, October 13, 2022
Emerald, SAN, News, CA, Cannabidiol, Orphan, MS, Stroke, Hope, Multiple sclerosis, Paper, HIF, Scleroderma, COO, Patient, Research, Traumatic brain injury, EHP, Technology, Company, Doctor of Philosophy, MD, Pharming, Systemic scleroderma, Safety, Degenerative disease, CNS, GLOBE, Forward-looking statement, Journal of Neuroinflammation, FDA, Autoimmunity, Pharmaceutical industry, EU

SAN DIEGO, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis (SSc) and multiple sclerosis (MS).

Key Points: 
  • This first-in-class activator of the HIF pathway via modulation of B55a provides a new mechanism to treat diseases where vascular integrity is compromised.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates for the treatment of CNS, autoimmune, and other diseases.
  • The Companys second product candidate, EHP-102, is in non-clinical development withIND-enabling studiesand is focused on treating Parkinsons disease and Huntingtons disease.
  • Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Retrieved on: 
Monday, August 8, 2022
People, U.S. Securities and Exchange Commission, Respiration (physiology), GLOBE, Caudate nucleus, SEC, Cancer, Brain, Behavior, Security (finance), Research, HD, Journal of Neuroinflammation, Diffuse axonal injury, Patient, Tumor microenvironment, Astrocyte, Neurodegeneration, Nature Medicine, Microfilament, Immunosuppression, Health, Disease, Government budget balance, HIV disease progression rates, Inflammation, Neuron, Immunoglobulin G, SEMA4D, Kaufman Assessment Battery for Children, Key finding attacks, Apathy, Nasdaq, Locomotion, Forward-looking statement, Microglia, SIGNAL, Caregiver, Neoplasm, Cell, COVID-19, Program, Mutation, Dementia, Atrophy, Cognition, B cell, FDG-PET, Company, Problem solving, Pharmaceutical industry, Medical imaging, Vaccine, Risk management, Journal

ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer’s disease (AD).

Key Points: 
  • These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD.
  • Accordingly, a phase 1b/2a study of pepinemab in Alzheimers disease has been initiated and is actively enrolling patients (NCT04381468).
  • The mechanism of action of pepinemab, targeting neuroinflammation2, may provide an alternative to other AD therapies that target aggregates of A amyloid.
  • The Nature Medicine publication is available online at https://www.nature.com/articles/s41591-022-01919-8 and Journal of Neuroinflammation at https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-022... ; both articles will also be posted on the Vaccinex website.

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Retrieved on: 
Tuesday, November 9, 2021
Neurodegeneration, Cognition, Securities Exchange Act of 1934, Safety, CSF, Neuroinflammation, Biomarker, Journal of Neuroinflammation, Disorder, Therapy, State Administrative Expenses, PET, AD, CGMP, Ageing, Pharmacology, Alzheimer's disease, Government budget balance, EEG, ADV, Administration, COVID-19, Securities Act of 1933, SGC, Workforce, MRI, CNS, Twitter, Conference, GLOBE, Development, NO, LinkedIn, Physiology, SEC, Pharmacokinetics, Maritime Transportation Security Act of 2002, Journal, Cognitive deficit, Pathology, CYCN, Nasdaq, Patient, Nitric oxide, Drug development, Brain, Guanylate cyclase, Pharmaceutical industry, Medical imaging, Lithium

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, reported today results for the third quarter 2021 and provided general corporate and pipeline updates.

Key Points: 
  • Research & Development Expenses: R&D expenses were approximately $7.0 million for the third quarter of 2021, as compared to approximately $13.7 million for the third quarter of 2020.
  • General and Administrative Expenses: G&A expenses were approximately $4.6 million for the third quarter of 2021, as compared to approximately $8.0 million for the third quarter of 2020.
  • Net Loss: Net loss was approximately $11.3 million for the third quarter of 2021, as compared to $18.8 million for the third quarter of 2020.
  • For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter ( @Cyclerion ) and LinkedIn ( www.linkedin.com/company/cyclerion ).

New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease

Retrieved on: 
Tuesday, October 5, 2021
Patent, Clinical trial, OTCQB, Annual report, Risk, Memory, Security (finance), Alzheimer's disease, Private Securities Litigation Reform Act, Depression, U.S. Securities and Exchange Commission, Cognitive behavioral therapy, George Washington University School of Engineering and Applied Science, Thymosin, Biochemistry, Disease, Form 10-K, Lists of diseases, Company, Government budget balance, George Washington University School of Medicine & Health Sciences, Drug combination, Journal, NF, Research, Human, Molecular medicine, Journal of Neuroinflammation, Learning, Forward-looking statement, Anxiety, SEC, Regeneration, Department, Pharmaceutical industry

The research team also observed that over-expression of T4 improved neuronal function and cognitive behavior performance and displayed anti-depressant-like effects.

Key Points: 
  • The research team also observed that over-expression of T4 improved neuronal function and cognitive behavior performance and displayed anti-depressant-like effects.
  • In the study, T4 down regulated certain known inflammatory pathways, while other drug combinations did not, in particular NF-B signaling.
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.
  • Forward-looking statements in this press release include but are not limited to statements from us or within research published by third parties.

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Retrieved on: 
Wednesday, September 22, 2021
MELAS, ADV, CNS, Therapy, Securities Act of 1933, Neurodegeneration, CD40, CGMP, NOX2, Alzheimer's disease, TNF, Pathology, Neuroinflammation, Traffic barrier, Physiology, LinkedIn, Biomarker, GFAP, Cognitive deficit, CIAS, Nitric oxide, Twitter, NO, Government budget balance, Pharmacology, Mitochondrial encephalomyopathy, Journal, Cognition, Research, CYCN, Drug development, Journal of Neuroinflammation, Securities Exchange Act of 1934, Nasdaq, Translational medicine, SEC, SGC, GLOBE, Disorder, Dietary supplement, Medical imaging

These data suggest that CNS penetrant sGC stimulators, such as Cyclerion development candidates CY6463 and CY3018, could provide therapeutic benefit to individuals living with CNS diseases associated with neuroinflammation.

Key Points: 
  • These data suggest that CNS penetrant sGC stimulators, such as Cyclerion development candidates CY6463 and CY3018, could provide therapeutic benefit to individuals living with CNS diseases associated with neuroinflammation.
  • CY6463 is the first brain-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases.
  • Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway.
  • The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases.